LBA2_PRAfatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
Park, K., Tan, E.-H., Zhang, L., Hirsh, V., O'Byrne, K., Boyer, M., Yang, J.C.-H., Mok, T., Kim, M., Massey, D., Zazulina, V., Paz-Ares, L.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv586.02
Date:
December, 2015
File:
PDF, 39 KB
english, 2015
File converter
More search results
More benefits 
